Evidence map›Paper›PMID 31441231›Full record

ArticleJournal of the International AIDS Society2019

HIV-1 DNA decay is faster in children who initiate ART shortly after birth than later.

Kirsten A Veldsman, Anita Janse van Rensburg, Shahieda Isaacs, Shalena Naidoo, Barbara Laughton, Carl Lombard, Mark F Cotton, John W Mellors, Gert U van Zyl

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Predictors of Cell-Associated Human Immunodeficiency Virus (HIV)-1 DNA Over 1 Year in Very Early Treated Infants.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Capitalizing on Postexposure Antiretroviral Prophylaxis to Restrict Seeding of the Human Immunodeficiency Virus Reservoir.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kirsten A VeldsmanDivision of Medical Virology, Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa.ORCID 0000-0001-6796-1787
Anita Janse van RensburgDepartment Pediatrics and Child Health, Tygerberg Children's Hospital and Family Clinical Research Unit, Stellenbosch University, Cape Town, South Africa.
Shahieda IsaacsDivision of Medical Virology, Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa.
Shalena NaidooDivision of Medical Virology, Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa.
Barbara LaughtonDepartment Pediatrics and Child Health, Tygerberg Children's Hospital and Family Clinical Research Unit, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0001-7260-7723
Carl LombardDivision of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Mark F CottonDepartment Pediatrics and Child Health, Tygerberg Children's Hospital and Family Clinical Research Unit, Stellenbosch University, Cape Town, South Africa.
John W MellorsDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Gert U van ZylDivision of Medical Virology, Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa.ORCID 0000-0003-3021-5101

Funding

The effect of ART on rates and transmission of TBU19AI053217 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI VIOLARI, AVY · 2002 to 2011
$44.9M
Combined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6M
Latent reservoir characterization and correlations with neurocognitive functioninR01MH105134 · NIMH · STELLENBOSCH UNIVERSITY · PI COTTON, MARK FREDRIC · 2014 to 2018
$3.1M
Characterizing HIV-1 diversity, evolution, and integration sites in children initiating cART in early infectionU01CA200441 · NCI · STELLENBOSCH UNIVERSITY · PI KEARNEY, MARY, VAN ZYL, GERT UVES · 2015 to 2019
$842k
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS U01 CA200441NIAID NIH HHS U19 AI053217NIAID NIH HHS UM1 AI126603NIMH NIH HHS R01 MH105134
6 · The paper itself

Abstract

introductionThere is limited data in children on whether persistence of HIV-1 infected cells is affected by age at initiating antiretroviral therapy (ART), its duration or any subsequent ART interruption. We therefore investigated the effects of both age of ART initiation and duration of ART interruption on HIV-1 DNA decay in children.

methodsWe investigated HIV-1 DNA decay in three groups of children on ART: Group-1 (n = 7) started uninterrupted ART within eight days of life; Group-2 (n = 8) started uninterrupted ART at a median of five months of age; and Group-3 (n = 23) started ART at a median age of 1.8 months for either 40 or 96 weeks, then interrupted ART (median of seven months), and restarted ART based on CD4 count and clinical criteria. Total HIV-1 DNA was assayed using a sensitive HIV-1 subtype C-adapted quantitative PCR for integrase. The duration of ART was square root transformed to fit the observed slowing of HIV-1 DNA decay rate. For each group, point estimates for decay rates were determined after six months of continuous suppressive ART in groups 1 and 2 or six months after restarting ART in Group-3. Groups-2 and 3 were combined using a mixed effect regression model to investigate covariates of HIV-1 DNA decay rate. RESULTS AND DISCUSSION: At six months of continuous suppressive ART, the HIV-1 DNA t½ (95% CI) was shorter in Group-1 (n = 7): 2.7 months (2.1 to 3.8), than 9.2 months (7.4 to 12.1) in Group-2 (n = 8); and 9.6 months (7.6 to 12.6) in Group-3 (n = 23) (p < 0.01). In multivariable analyses, HIV-1 DNA before treatment (p < 0.001) and the change in HIV-1 DNA during interruption (p < 0.01) were independent predictors of slower HIV-1 DNA decay.

conclusionsThese data suggest that ART initiation within the first week of life can reduce the persistence of long-lived infected cells. Delaying ART is associated with slower decay of infected cells.

Indexed as

Time-to-TreatmentAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountChild, PreschoolDNA, ViralDrug Administration ScheduleHIV-1HIV InfectionsHumansInfantInfant, NewbornAnti-HIV AgentsDNA, ViralAfricaearly infant HIV-1 diagnosisearly treatmentHIV-1 DNA kineticsHIV-1 persistencepaediatrics

Identifiers

PMID31441231
PMCPMC6868516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.